Merck's Dr Dave Maraldo outlines 3 principles for placing manufacturing capacity and how end-to-end ADC supply chains could shift platform thinking.
|Articles|November 15, 2014
- BioPharm International-11-15-2014
- Volume 2104 eBook
- Issue 4
Optimizing Resin Performance with Disposable Chromatography Solutions
Author(s)Randi Hernandez
An increased need for higher-capacity resins and the demand for smaller batches has made disposable chromatography a more viable option.
Advertisement
Although the initial uptake of single-use chromatography solutions has been relatively slow, an increased need for higher-capacity resins and the demand for smaller batches has made disposable chromatography a more viable option.
from BioPharm International’s 2014 Secure Single-Use Systems eBook.
Articles in this issue
about 12 years ago
Innovations in Single-Use Bioprocessing Componentsabout 12 years ago
Budgets Increase to Support Single-Use Bioprocessingabout 12 years ago
Security of the Single-Use Supply Chain: Is Dual Sourcing the Answer?about 12 years ago
Trends in Single-Use BioreactorsAdvertisement
Related to this article
Donidalorsen sustained a 95% reduction in hereditary angioedema attacks over 2 years, and patients switching from other prophylaxis saw a 71% drop.
A single 240 mg dose of WVE-007 cut visceral fat while preserving lean mass for 1 year, as Activin E fell by up to 88% across INLIGHT dose groups.
This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Advertisement
Advertisement
Trending on BioPharm International
1
Zai Lab’s Long-Acting Atopic Dermatitis Bispecific Points to Every-12-Week Dosin
2
FDA Grants Kamau RMAT Designation to Nula-cel for Sickle Cell Disease
3
Wave Reports 1-Year INLIGHT Data for INHBE siRNA WVE-007 in Obesity
4
What 3 Principles Guide Merck's Biologics and ADC Capacity Placement?
5